| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
John W Childs is Director at BHVN, with reported holdings spanning 2 companies. John W Childs's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $114.2M at current prices.
Our model assigns John W Childs a middling insider score of 59/100, based on 14 past trades. Over a 12-month horizon, 41.7% of those trades were profitable, with an average 12-month return of +5.2%.
John W Childs's largest disclosed position is in BHVN as Director, worth about $88.3M. Net of sales, the BHVN filings show accumulation of 8,474,792 shares.
John W Childs has 23 Form 4 filings on record from October 2022 to August 2026, across 2 companies: Director at Veradermics (MANE), 2026; Director at Biohaven (BHVN), 2022–2026.
The 42 reported transactions were 21 open-market purchases, 6 option or other derivative awards, 4 other transactions and 3 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 14 purchases worth about $100.4M and 1 sale worth about $10.7M.
The largest open-market purchase was 3,900,000 shares of BHVN at an average $10.50 on October 25, 2022, about $41.0M. Twelve months later BHVN was up 92%.
The only open-market sale was 100,000 shares of MANE at an average $107.12 on August 12, 2026, about $10.7M.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | MANE Veradermics, Incorporated | Director | Sell | 100,000 | $107.12 | $10,711,700.00 | -34.0% | - | - | |
| Feb 5, 2026 | MANE Veradermics, Incorporated | Director | Buy | 294,117 | $17.00 | $4,999,989.00 | +15.4% | +195.4% | - | |
| Nov 13, 2025 | BHVN Biohaven Ltd. | Director | Buy | 3,333,333 | $7.50 | $24,999,997.50 | +143.6% | +45.8% | - | |
| Mar 4, 2025 | BHVN Biohaven Ltd. | Director | Buy | 32,700 | $30.47 | $996,238.47 | -441.4% | -50.0% | -66.2% | |
| Dec 30, 2024 | BHVN Biohaven Ltd. | Director | Buy | 29,000 | $35.94 | $1,042,393.40 | +1.2% | -32.8% | -67.5% | |
| Oct 2, 2024 | BHVN Biohaven Ltd. | Director | Buy | 21,052 | $47.50 | $999,970.00 | New | -22.2% | -67.7% | |
| Jul 18, 2024 | BHVN Biohaven Ltd. | Director | Buy | 28,400 | $35.67 | $1,012,982.56 | +1.2% | +48.3% | -59.5% | |
| May 30, 2024 | BHVN Biohaven Ltd. | Director | Buy | 28,000 | $35.58 | $996,240.00 | +1.2% | +16.4% | -58.0% | |
| May 13, 2024 | BHVN Biohaven Ltd. | Director | Buy | 28,500 | $35.17 | $1,002,470.40 | +1.3% | +9.4% | -42.2% | |
| Apr 22, 2024 | BHVN Biohaven Ltd. | Director | Buy | 195,121 | $41.00 | $7,999,961.00 | +9.5% | -4.9% | -44.8% |